Familial Lipoprotein Lipase Deficiency – Pipeline Insight, 2022

DelveInsight’s, Familial Lipoprotein Lipase Deficiency Pipeline Insight, 2022,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Familial Lipoprotein Lipase Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Familial Lipoprotein Lipase Deficiency Overview

Familial Lipoprotein Lipase Deficiency (LPLD), also known as Familial Chylomicronemia Syndrome (FCS) is a rare inherited condition, in which the normal breakdown of fats in the body is affected. The condition is inherited in an autosomal recessive pattern. In the past, familial lipoprotein lipase deficiency has also been called hyperlipoproteinemia type I. This deficiency is usually caused by a defect in the LPL gene, which encodes for an enzyme called lipoprotein lipase.

 

Download sample report @ Familial Lipoprotein Lipase Deficiency Pipeline Report

 

Familial Lipoprotein Lipase Deficiency Diagnosis

A diagnosis of Familial Lipoprotein Lipase Deficiency may be done based upon identification of characteristic symptoms, a detailed patient history, and a thorough clinical evaluation. Blood tests can reveal reduced activity of the lipoprotein lipase enzyme in the plasma. Treatment for Familial Lipoprotein Lipase Deficiency aims to control the symptoms and blood triglyceride levels with a very low-fat diet. Drugs that lower lipid levels in the body are not effective in reducing fat levels.

 

Familial Lipoprotein Lipase Deficiency Pipeline Insights

“Familial Lipoprotein Lipase Deficiency – Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Familial Lipoprotein Lipase Deficiency pipeline landscape is provided which includes the disease overview and Familial Lipoprotein Lipase Deficiency treatment guidelines.

The assessment part of the report embraces, in depth Familial Lipoprotein Lipase Deficiency commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Familial Lipoprotein Lipase Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Familial Lipoprotein Lipase Deficiency Pipeline Companies

• Amryt Pharma

• Arrowhead Pharmaceuticals

• Ionis Pharmaceuticals

• iMetabolic Biopharma

• Precision Biosciences

• Pfizer

• Lipigon Pharmaceuticals

 

Familial Lipoprotein Lipase Deficiency Emerging Drugs

 

IONIS-APOCIII-LRx: Ionis Pharmaceuticals

IONIS-APOCIII-LRx, formerly known as AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III, for patients who are at risk of disease due to elevated triglyceride levels. The drug is in Phase III clinical evaluation for the treatment of familial lipoprotein lipase deficiency. 

 

ARO-APOC3: Arrowhead Pharmaceuticals

ARO-APOC3 is a subcutaneously administered RNAi therapeutic that targets apolipoprotein C-III (apoC-III), and reduces VLDL synthesis and assembly, enhances the breakdown of triglyceride rich lipoproteins, and improve clearance of VLDL and chylomicron remnants. The drug is in Phase II clinical studies for the treatment of familial lipoprotein lipase deficiency.

 

Familial Lipoprotein Lipase Deficiency Pipeline Report Insights

Familial Lipoprotein Lipase Deficiency Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

 

Familial Lipoprotein Lipase Deficiency Pipeline Report Assessment

Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

 

Request Sample Report @ Familial Lipoprotein Lipase Deficiency Pipeline Drugs

 

Table of content

Introduction
Executive Summary
Familial Lipoprotein Lipase Deficiency: Overview
Pipeline Therapeutics
Therapeutic Assessment
Familial Lipoprotein Lipase Deficiency – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
IONIS-APOCIII-LRx: Ionis Pharmaceuticals
Mid Stage Products (Phase II)
ARO-APOC3: Arrowhead Pharmaceuticals
Early Stage Products (Phase I/II)
Drug name: Company name
Preclinical/Discovery Stage Products
Lipisense: Lipigon Pharmaceuticals
Inactive Products
Familial Lipoprotein Lipase Deficiency Key Companies
Familial Lipoprotein Lipase Deficiency Key Products
Familial Lipoprotein Lipase Deficiency- Unmet Needs
Familial Lipoprotein Lipase Deficiency- Market Drivers and Barriers
Familial Lipoprotein Lipase Deficiency- Future Perspectives and Conclusion
Familial Lipoprotein Lipase Deficiency Analyst Views
Appendix

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/